SG10201900144TA - Pyridone derivative having tetrahydropyranylmethyl group - Google Patents
Pyridone derivative having tetrahydropyranylmethyl groupInfo
- Publication number
- SG10201900144TA SG10201900144TA SG10201900144TA SG10201900144TA SG10201900144TA SG 10201900144T A SG10201900144T A SG 10201900144TA SG 10201900144T A SG10201900144T A SG 10201900144TA SG 10201900144T A SG10201900144T A SG 10201900144TA SG 10201900144T A SG10201900144T A SG 10201900144TA
- Authority
- SG
- Singapore
- Prior art keywords
- salt
- pyridone derivative
- ofaxl
- treatment
- hyperfunction
- Prior art date
Links
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 title abstract 3
- 125000006173 tetrahydropyranylmethyl group Chemical group 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000013078 crystal Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014139628 | 2014-07-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201900144TA true SG10201900144TA (en) | 2019-02-27 |
Family
ID=55064330
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201900144TA SG10201900144TA (en) | 2014-07-07 | 2015-07-06 | Pyridone derivative having tetrahydropyranylmethyl group |
SG11201700063RA SG11201700063RA (en) | 2014-07-07 | 2015-07-06 | Pyridone derivative having tetrahydropyranylmethyl group |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201700063RA SG11201700063RA (en) | 2014-07-07 | 2015-07-06 | Pyridone derivative having tetrahydropyranylmethyl group |
Country Status (28)
Country | Link |
---|---|
US (3) | US10442797B2 (fr) |
EP (2) | EP3868757A1 (fr) |
JP (2) | JP6086516B2 (fr) |
KR (1) | KR102348190B1 (fr) |
CN (2) | CN111467346B (fr) |
AU (1) | AU2015288648B2 (fr) |
BR (1) | BR112017000242A2 (fr) |
CA (1) | CA2954488C (fr) |
CO (1) | CO2017001178A2 (fr) |
CY (1) | CY1124537T1 (fr) |
DK (1) | DK3168219T3 (fr) |
ES (1) | ES2875360T3 (fr) |
HR (1) | HRP20210899T1 (fr) |
HU (1) | HUE054534T2 (fr) |
IL (2) | IL249948B (fr) |
LT (1) | LT3168219T (fr) |
MX (1) | MX2017000330A (fr) |
MY (1) | MY194307A (fr) |
PH (1) | PH12017500048A1 (fr) |
PL (1) | PL3168219T3 (fr) |
PT (1) | PT3168219T (fr) |
RS (1) | RS61941B1 (fr) |
RU (1) | RU2707953C2 (fr) |
SG (2) | SG10201900144TA (fr) |
SI (1) | SI3168219T1 (fr) |
TW (2) | TWI723572B (fr) |
WO (1) | WO2016006706A1 (fr) |
ZA (1) | ZA201700139B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
WO2017146236A1 (fr) | 2016-02-26 | 2017-08-31 | 小野薬品工業株式会社 | Médicament pour le traitement du cancer caractérisé par l'administration d'une association d'un inhibiteur de l'axl et d'un inhibiteur de point de contrôle immunitaire |
CN108250200A (zh) * | 2016-12-28 | 2018-07-06 | 中国科学院上海药物研究所 | 一种具有Axl抑制活性的化合物及其制备和应用 |
TWI796326B (zh) * | 2017-03-24 | 2023-03-21 | 日商第一三共股份有限公司 | 含有axl抑制劑與egfr酪胺酸激酶抑制藥的醫藥品及其用途 |
EP3673907A4 (fr) | 2017-08-23 | 2020-08-19 | ONO Pharmaceutical Co., Ltd. | Produit pharmaceutique destiné au traitement du cancer comprenant un inhibiteur d'axl en tant que principe actif |
JP7223998B2 (ja) | 2017-10-13 | 2023-02-17 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含む固形がん治療剤 |
CN112088157B (zh) * | 2017-12-22 | 2023-12-26 | 拉文纳制药公司 | 作为磷脂酰肌醇磷酸激酶抑制剂的芳基-联吡啶胺衍生物 |
EP3741752A4 (fr) * | 2018-01-17 | 2021-05-26 | Nanjing Transthera Biosciences Co., Ltd. | Inhibiteur de kinase de la famille tam/et csf1r et son utilisation |
CN112243374A (zh) * | 2018-01-29 | 2021-01-19 | 卡普勒斯疗法有限责任公司 | 包括6元中心环的srebp抑制剂 |
EP3819296B1 (fr) | 2018-07-04 | 2022-06-29 | Daiichi Sankyo Company, Limited | Procédé de production de dérivés de diarylpyridine |
KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
WO2021089791A1 (fr) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
WO2022220227A1 (fr) * | 2021-04-14 | 2022-10-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Composé de tétrahydropyridopyrimidine |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1136485A1 (fr) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | Dérivés d' aminophénylpyrimidinone |
GB0319241D0 (en) | 2003-08-15 | 2003-09-17 | Hotpods Ltd | Oven and a food delivery vehicle comprising said oven |
WO2007030680A2 (fr) | 2005-09-07 | 2007-03-15 | Rigel Pharmaceuticals, Inc. | Derives de triazole utiles comme inhibiteurs d'axl |
WO2007057399A2 (fr) | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Traitement du cancer |
US7825137B2 (en) | 2005-12-05 | 2010-11-02 | Pfizer Inc. | Method of treating abnormal cell growth |
JP5400388B2 (ja) | 2005-12-15 | 2014-01-29 | ライジェル ファーマシューティカルズ, インコーポレイテッド | キナーゼインヒビターおよびその利用 |
EP1900727A1 (fr) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Derivés d'aminopyridine en tant qu'inhibiteurs de kinases |
WO2008045978A1 (fr) | 2006-10-10 | 2008-04-17 | Rigel Pharmaceuticals, Inc. | Dérivés de pyrimidinediamine substitués par du pinane, utiles en tant qu'inhibiteurs de axl |
GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
PT2114955E (pt) | 2006-12-29 | 2013-04-18 | Rigel Pharmaceuticals Inc | Triazoles substituídos com arilo bicíclico em ponte ou heteroarilo bicíclico em ponte úteis como inibidores de axl |
ME01832B (me) | 2006-12-29 | 2014-12-20 | Rigel Pharmaceuticals Inc | Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori |
ES2406930T3 (es) | 2006-12-29 | 2013-06-10 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL |
JP5567837B2 (ja) | 2006-12-29 | 2014-08-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Axlインヒビターとして有用なN3−ヘテロアリール置換トリアゾールおよびN5−ヘテロアリール置換トリアゾール |
CA2946305C (fr) | 2006-12-29 | 2019-09-17 | Rigel Pharmaceuticals, Inc. | Triazoles substitues utilises comme inhibiteurs d'axl |
EP2139869A2 (fr) | 2007-04-13 | 2010-01-06 | SuperGen, Inc. | Inhibiteurs de la kinase axl utiles pour le traitement du cancer ou de maladies hyperprolifératives |
US20100261723A1 (en) | 2007-07-09 | 2010-10-14 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
GB0713259D0 (en) | 2007-07-09 | 2007-08-15 | Astrazeneca Ab | Pyrazine derivatives 954 |
WO2009024825A1 (fr) | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | Dérivés de 2-pyrazinylbenzimidazole en tant qu'inhibiteurs des récepteurs tyrosine kinase |
GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
RU2010120536A (ru) * | 2007-10-25 | 2011-11-27 | Астразенека Аб (Se) | Производные пиридина и пиразина, полезные для лечения клеточных проферативных расстройств |
WO2009053737A2 (fr) | 2007-10-25 | 2009-04-30 | Astrazeneca Ab | Dérivés de pyridine et de pyrazine - 083 |
CA2704052C (fr) | 2007-10-26 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Triazoles substitues par aryle polycyclique et triazoles substitues par heteroaryle polycyclique utiles comme inhibiteurs d'axl |
AU2008318854A1 (en) | 2007-11-02 | 2009-05-07 | Janssen Pharmaceutica, N.V. | Use of CFMS inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer |
JP5693239B2 (ja) | 2008-01-23 | 2015-04-01 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 4−ピリジノン化合物および癌についてのその使用 |
JP5314050B2 (ja) | 2008-01-23 | 2013-10-16 | ブリストル−マイヤーズ スクイブ カンパニー | 4−ピリジノン化合物および癌についてのその使用 |
CA2718538A1 (fr) | 2008-04-16 | 2009-10-22 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Derives de quinolines utilises comme inhibiteurs des kinases axl |
UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
WO2009138799A1 (fr) | 2008-05-14 | 2009-11-19 | Astex Therapeutics Limited | Utilisation thérapeutique de la 1-cyclopropyl-3-[3-(5-morpholin-4-ylméthyl-1h-benzoimidazol-2-yl)-lh-pyrazol-4-yl]-urée |
US8431594B2 (en) | 2008-07-09 | 2013-04-30 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors |
WO2010005876A2 (fr) | 2008-07-09 | 2010-01-14 | Rigel Pharmaceuticals, Inc. | Triazoles à substitution hétéroaryle polycycliques utiles en tant qu’inhibiteurs d’axl |
US20100204221A1 (en) | 2009-02-09 | 2010-08-12 | Hariprasad Vankayalapati | Pyrrolopyrimidinyl axl kinase inhibitors |
JP2012525336A (ja) * | 2009-04-27 | 2012-10-22 | エラン ファーマシューティカルズ,インコーポレイテッド | α−4インテグリンのピリジノンアンタゴニスト |
EP2311809A1 (fr) | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
US8962623B2 (en) | 2011-03-04 | 2015-02-24 | Locus Pharmaceuticals, Inc. | Aminopyrazine compounds |
ES2617484T3 (es) * | 2012-01-31 | 2017-06-19 | Daiichi Sankyo Company, Limited | Derivado de piridona |
WO2013162061A1 (fr) | 2012-04-26 | 2013-10-31 | 第一三共株式会社 | Composé de pyrimidine bicyclique |
TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
-
2015
- 2015-07-03 TW TW108136526A patent/TWI723572B/zh active
- 2015-07-03 TW TW104121592A patent/TWI690525B/zh active
- 2015-07-06 SG SG10201900144TA patent/SG10201900144TA/en unknown
- 2015-07-06 DK DK15818440.8T patent/DK3168219T3/da active
- 2015-07-06 EP EP21166082.4A patent/EP3868757A1/fr active Pending
- 2015-07-06 JP JP2016532991A patent/JP6086516B2/ja active Active
- 2015-07-06 ES ES15818440T patent/ES2875360T3/es active Active
- 2015-07-06 CN CN202010427596.9A patent/CN111467346B/zh active Active
- 2015-07-06 CN CN201580047744.1A patent/CN106604920B/zh active Active
- 2015-07-06 PL PL15818440T patent/PL3168219T3/pl unknown
- 2015-07-06 RU RU2017103753A patent/RU2707953C2/ru active
- 2015-07-06 WO PCT/JP2015/069976 patent/WO2016006706A1/fr active Application Filing
- 2015-07-06 PT PT158184408T patent/PT3168219T/pt unknown
- 2015-07-06 HU HUE15818440A patent/HUE054534T2/hu unknown
- 2015-07-06 BR BR112017000242-6A patent/BR112017000242A2/pt active IP Right Grant
- 2015-07-06 KR KR1020177000534A patent/KR102348190B1/ko active IP Right Grant
- 2015-07-06 MY MYPI2017000012A patent/MY194307A/en unknown
- 2015-07-06 CA CA2954488A patent/CA2954488C/fr active Active
- 2015-07-06 MX MX2017000330A patent/MX2017000330A/es unknown
- 2015-07-06 LT LTEP15818440.8T patent/LT3168219T/lt unknown
- 2015-07-06 SI SI201531589T patent/SI3168219T1/sl unknown
- 2015-07-06 AU AU2015288648A patent/AU2015288648B2/en active Active
- 2015-07-06 SG SG11201700063RA patent/SG11201700063RA/en unknown
- 2015-07-06 US US15/036,981 patent/US10442797B2/en active Active
- 2015-07-06 RS RS20210707A patent/RS61941B1/sr unknown
- 2015-07-06 EP EP15818440.8A patent/EP3168219B1/fr active Active
-
2017
- 2017-01-05 IL IL249948A patent/IL249948B/en active IP Right Grant
- 2017-01-06 PH PH12017500048A patent/PH12017500048A1/en unknown
- 2017-01-06 ZA ZA2017/00139A patent/ZA201700139B/en unknown
- 2017-02-01 JP JP2017016682A patent/JP6203439B2/ja active Active
- 2017-02-07 CO CONC2017/0001178A patent/CO2017001178A2/es unknown
-
2019
- 2019-09-18 US US16/575,177 patent/US11208403B2/en active Active
-
2020
- 2020-10-18 IL IL278124A patent/IL278124B/en unknown
-
2021
- 2021-06-07 HR HRP20210899TT patent/HRP20210899T1/hr unknown
- 2021-06-30 CY CY20211100586T patent/CY1124537T1/el unknown
- 2021-08-12 US US17/400,795 patent/US20220002277A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201900144TA (en) | Pyridone derivative having tetrahydropyranylmethyl group | |
PH12014501719A1 (en) | Pyridone derivatives | |
PH12015502737A1 (en) | Novel fused pyrimidine compound or salt thereof | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
PH12014502396B1 (en) | Nitrogenated heterocyclic compound | |
PH12015501585A1 (en) | Manufacturing process for pyrimidine derivatives | |
PH12016500225B1 (en) | Novel quinoline-substituted compound | |
TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
MA38982A1 (fr) | Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl | |
MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
NZ738836A (en) | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid | |
MX359069B (es) | Sal y formas cristalinas de inhibidor de quinasa tipo polo-4. | |
PH12016501941B1 (en) | Use of heterocyclic compounds for controlling nematodes | |
MX2013007937A (es) | Nuevo derivado de indol o indazol o sal del mismo. | |
IN2013DE02503A (fr) | ||
PH12016501645A1 (en) | Aminopyrazolone derivative | |
WO2016014864A8 (fr) | Hydroxy-(r)-2,2'-bisméthylnaltrexones et leurs utilisations | |
PH12017500492A1 (en) | Crystalline bace inhibitors | |
PH12014502780A1 (en) | Azetidine and piperidine compounds useful as pde10 inhibitors | |
GB2527958A (en) | Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents | |
TN2013000094A1 (en) | Manufacturing process for pyrimidine derivatives | |
TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors |